Neuropsychiatric Symptoms in Parkinson's Disease: Beyond Complications.
作者信息
Kehagia Angie A
机构信息
Institute of Psychiatry, Psychology and Neuroscience, King's College London , London , UK.
出版信息
Front Psychiatry. 2016 Jun 23;7:110. doi: 10.3389/fpsyt.2016.00110. eCollection 2016.
Abstract
摘要
相似文献
1
Neuropsychiatric Symptoms in Parkinson's Disease: Beyond Complications.
Front Psychiatry. 2016 Jun 23;7:110. doi: 10.3389/fpsyt.2016.00110. eCollection 2016.
2
Neuropsychiatric manifestations of Parkinson's disease.
Australas Psychiatry. 2016 Dec;24(6):529-533. doi: 10.1177/1039856216654393. Epub 2016 Jul 25.
3
A comprehensive overview of the neuropsychiatry of Parkinson's disease: A review.
Bull Menninger Clin. 2017 Winter;81(1):53-105. doi: 10.1521/bumc.2017.81.1.53.
4
Commentary on "The Neuropsychiatry of Parkinson's Disease: A Perfect Storm".
Am J Geriatr Psychiatry. 2019 Sep;27(9):1019-1021. doi: 10.1016/j.jagp.2019.03.007. Epub 2019 Mar 20.
5
Neuropsychiatric co-morbidities in non-demented Parkinson's disease.
Ann Indian Acad Neurol. 2015 Jan-Mar;18(1):33-8. doi: 10.4103/0972-2327.144287.
6
Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia.
Psychiatry Clin Neurosci. 2014 Sep;68(9):692-700. doi: 10.1111/pcn.12175. Epub 2014 Apr 14.
7
A guide to management of neuropsychiatric manifestations of Parkinson's disease.
Australas Psychiatry. 2016 Dec;24(6):534-537. doi: 10.1177/1039856216654394. Epub 2016 Jun 21.
8
Impact of Neuropsychiatric Symptoms on the Quality of Life of Subjects with Parkinson's Disease.
J Parkinsons Dis. 2015;5(3):541-8. doi: 10.3233/JPD-150597.
9
Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson's Disease Dementia.
J Mov Disord. 2015 May;8(2):98-102. doi: 10.14802/jmd.15041. Epub 2015 May 31.
10
Range of neuropsychiatric disturbances in patients with Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1999 Oct;67(4):492-6. doi: 10.1136/jnnp.67.4.492.
引用本文的文献
1
Diosgenin derivative ML5 attenuates MPTP-induced neuronal impairment via regulating AMPK/PGC-1α-mediated mitochondrial biogenesis and fusion/fission.
Am J Transl Res. 2024 Aug 15;16(8):3582-3598. doi: 10.62347/JBRE5043. eCollection 2024.
2
White matter hyperintensities and smaller cortical thickness are associated with neuropsychiatric symptoms in neurodegenerative and cerebrovascular diseases.
Alzheimers Res Ther. 2023 Jun 20;15(1):114. doi: 10.1186/s13195-023-01257-y.
3
Compound Dihuang Granule Inhibits Nigrostriatal Pathway Apoptosis in Parkinson's Disease by Suppressing the JNK/AP-1 Pathway.
Front Pharmacol. 2021 Apr 8;12:621359. doi: 10.3389/fphar.2021.621359. eCollection 2021.
4
COVID-19 Pandemic and Psychiatric Symptoms: The Impact on Parkinson's Disease in the Elderly.
Front Psychiatry. 2020 Nov 27;11:581144. doi: 10.3389/fpsyt.2020.581144. eCollection 2020.
5
Dopamine Buffering Capacity Imaging: A Pharmacodynamic fMRI Method for Staging Parkinson Disease.
Front Neurol. 2020 May 6;11:370. doi: 10.3389/fneur.2020.00370. eCollection 2020.
6
Da-Bu-Yin-Wan and Qian-Zheng-San Ameliorate Mitochondrial Dynamics in the Parkinson's Disease Cell Model Induced by MPP.
Front Pharmacol. 2019 Apr 24;10:372. doi: 10.3389/fphar.2019.00372. eCollection 2019.
7
A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson's Disease.
J Parkinsons Dis. 2019;9(1):63-71. doi: 10.3233/JPD-181448.
8
Treatment of Parkinson's disease psychosis.
Med Int Rev. 2017 Dec;27(109):266-271. Epub 2018 Feb 3.
9
Mapping movement, mood, motivation and mentation in the subthalamic nucleus.
R Soc Open Sci. 2018 Jul 18;5(7):171177. doi: 10.1098/rsos.171177. eCollection 2018 Jul.
10
Management of Psychosis in a Patient with Probable Dopa-Responsive Dystonia.
Case Rep Psychiatry. 2018 Jun 14;2018:8040491. doi: 10.1155/2018/8040491. eCollection 2018.
本文引用的文献
1
Review of delirium in patients with Parkinson's disease.
J Neurol. 2015 Nov;262(11):2401-10. doi: 10.1007/s00415-015-7760-1. Epub 2015 May 10.
2
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Lancet. 2014 Feb 8;383(9916):533-40. doi: 10.1016/S0140-6736(13)62106-6. Epub 2013 Nov 1.
3
Risk of Parkinson disease after depression: a nationwide population-based study.
Neurology. 2013 Oct 22;81(17):1538-44. doi: 10.1212/WNL.0b013e3182a956ad. Epub 2013 Oct 2.
4
The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease.
Brain. 2013 Jul;136(Pt 7):2120-9. doi: 10.1093/brain/awt152.
5
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease.
Eur J Neurol. 2013 Jan;20(1):16-34. doi: 10.1111/ene.12022.
6
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment.
Lancet Neurol. 2012 Aug;11(8):697-707. doi: 10.1016/S1474-4422(12)70152-7.
7
Parkinson's disease: the quintessential neuropsychiatric disorder.
Mov Disord. 2011 May;26(6):1022-31. doi: 10.1002/mds.23664.
8
Impulse control disorders in Parkinson's disease: seeking a roadmap toward a better understanding.
Brain Struct Funct. 2011 Nov;216(4):289-99. doi: 10.1007/s00429-011-0314-0. Epub 2011 May 4.
9
Quetiapine in the treatment of psychosis in Parkinson's disease.
Ther Adv Neurol Disord. 2010 Nov;3(6):339-50. doi: 10.1177/1756285610389656.
10
Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues.
Arch Neurol. 2011 Feb;68(2):165. doi: 10.1001/archneurol.2010.260. Epub 2010 Oct 11.
Zotero 插件